Show simple item record

dc.contributor.authorLjungman, P
dc.contributor.authorDe Witte, T
dc.contributor.authorVerdonck, L
dc.contributor.authorGahrton, G
dc.contributor.authorFreycon, F
dc.contributor.authorGravett, P
dc.contributor.authorMcCann, S
dc.contributor.authorMorgenstern, Godfrey R
dc.contributor.authorNikoskelainen, J
dc.contributor.authorPowles, R
dc.date.accessioned2010-05-25T12:02:21Z
dc.date.available2010-05-25T12:02:21Z
dc.date.issued1993-05
dc.identifier.citationBone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. 1993, 84 (1):61-6 Br. J. Haematol.en
dc.identifier.issn0007-1048
dc.identifier.pmid8338779
dc.identifier.doi10.1111/j.1365-2141.1993.tb03025.x
dc.identifier.urihttp://hdl.handle.net/10541/99780
dc.description.abstractThe optimal post-remission therapy for patients with acute myeloblastic leukaemia remains controversial. Allogeneic bone marrow transplantation, autologous bone marrow transplantation, and consolidation chemotherapy are the major options. In order to evaluate their respective value the European Group for Bone Marrow Transplantation conducted a prospective registration study. Patients with newly diagnosed acute myeloblastic leukaemia were registered at the time of HLA-typing and intention to treat in case of presence or absence of an HLA-identical donor was recorded. 27/79 (34%) patients HLA-typed at diagnosis had an identical donor identified. The estimated survivals at 3 years from HLA-typing were 44% and 21% among patients with or without HLA-identical donor, respectively (P = 0.02). 22/26 (85%) patients for whom allogeneic bone marrow transplantation was intended were transplanted but only 15/47 (32%) patients for whom autologous bone marrow transplantation was intended were indeed transplanted (P < 0.001). The survival was 50%, 29% and 17% (P = 0.004) for patients treated with allogeneic bone marrow transplantation, autologous bone marrow transplantation, or chemotherapy, respectively. 40/68 patients HLA-typed in first complete remission had an HLA-identical donor. The estimated 3-year survival among patients typed in first remission with and without HLA-identical donors was 42% and 35% (n.s.), respectively. This technique of early patient registration illustrates the problems of patient selection during the course of the disease and might be used as a complement to randomized trials when comparing bone marrow transplantation and other treatment options.
dc.language.isoenen
dc.subjectAcute Myeloid Leukaemiaen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBone Marrow Transplantation
dc.subject.meshHLA Antigens
dc.subject.meshHistocompatibility Testing
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshMiddle Aged
dc.subject.meshProspective Studies
dc.subject.meshTransplantation, Autologous
dc.subject.meshTransplantation, Homologous
dc.subject.meshTreatment Outcome
dc.titleBone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Huddinge University Hospital, Sweden.en
dc.identifier.journalBritish Journal of Haematologyen
html.description.abstractThe optimal post-remission therapy for patients with acute myeloblastic leukaemia remains controversial. Allogeneic bone marrow transplantation, autologous bone marrow transplantation, and consolidation chemotherapy are the major options. In order to evaluate their respective value the European Group for Bone Marrow Transplantation conducted a prospective registration study. Patients with newly diagnosed acute myeloblastic leukaemia were registered at the time of HLA-typing and intention to treat in case of presence or absence of an HLA-identical donor was recorded. 27/79 (34%) patients HLA-typed at diagnosis had an identical donor identified. The estimated survivals at 3 years from HLA-typing were 44% and 21% among patients with or without HLA-identical donor, respectively (P = 0.02). 22/26 (85%) patients for whom allogeneic bone marrow transplantation was intended were transplanted but only 15/47 (32%) patients for whom autologous bone marrow transplantation was intended were indeed transplanted (P < 0.001). The survival was 50%, 29% and 17% (P = 0.004) for patients treated with allogeneic bone marrow transplantation, autologous bone marrow transplantation, or chemotherapy, respectively. 40/68 patients HLA-typed in first complete remission had an HLA-identical donor. The estimated 3-year survival among patients typed in first remission with and without HLA-identical donors was 42% and 35% (n.s.), respectively. This technique of early patient registration illustrates the problems of patient selection during the course of the disease and might be used as a complement to randomized trials when comparing bone marrow transplantation and other treatment options.


This item appears in the following Collection(s)

Show simple item record